Tenderwize
Back to tender search

Open House Original Discount Agreements 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 434 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid (Wirkstoffkombination)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No guaranteed purchase volumes; revenue depends on market uptake.

Legal recourse is to social courts, not procurement review bodies; may be unfamiliar.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of discount agreements for the supply of Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid (HIV drug combination) to TK and participating insurance funds.
  • Contractual terms are non-negotiable and uniform for all participants.
Show full summary

Open House procedure by Techniker Krankenkasse (TK) to conclude discount agreements (Rabattverträge) for the active ingredient combination Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid. All eligible pharmaceutical entrepreneurs can join at any time during the contract period. No competitive selection; contracts are concluded with all meeting the eligibility criteria. Contract duration max 24 months from 01.11.2025 to 31.10.2027, with early termination upon patent expiry. No estimated value provided.

Risks

No guaranteed purchase volumes; revenue depends on market uptake.

Legal recourse is to social courts, not procurement review bodies; may be unfamiliar.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered drug.
  • Must hold a valid marketing authorization for the drug combination or be entitled to place it on the market.
  • Must have seat in Germany, another EU Member State, or EEA state (§9 Abs. 2 AMG).

Requirements may be incomplete.

Award Criteria

Lot 1

No competitive award; contract concluded with all eligible pharmaceutical entrepreneurs.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Original Discount Agreements 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid

Single lot for discount agreements on the specified HIV drug combination. Open to all eligible pharmaceutical entrepreneurs. No exclusivity, uniform conditions.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Oct 2025 - Oct 2027

Category

Pharmaceutical products

Award Criteria

No competitive award; contract concluded with all eligible pharmaceutical entrepreneurs.

Deadline

Deadline Oct 30, 2027

Procurement Details

Publication date
21 Aug 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
548037-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3